← FDA DRUG APPROVALS

FDA ANDA · ANDA076335

TRI-PREVIFEM

Sponsor: PH HEALTH

APPLICATION
ANDA076335
TYPE
ANDA
ORIGINAL APPROVAL
2004-03-26
LATEST ACTION
2022-04-29
ROUTE
ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

TRI-PREVIFEMDiscontinued
ETHINYL ESTRADIOL 0.035MG,0.035MG,0.035MG, NORGESTIMATE 0.18MG,0.215MG,0.25MG · TABLET · ORAL-28

Approval history

2022-04-29Labeling · Supplement 21 · standardAP
2022-02-03Labeling · Supplement 20 · standardAP
2016-02-24Manufacturing (CMC) · Supplement 16 · unknownAP
2016-02-24Labeling · Supplement 19 · standardAP
2014-12-19Labeling · Supplement 17 · standardAP
2013-01-03Labeling · Supplement 14 · standardAP
2004-03-26OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →